Clinical Trials Logo
  1. Home
  2. Carcinoma, Small Cell Lung
  3. NCT00435578

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Carcinoma, Small Cell Lung Clinical Trial

Official title:
An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Clinical Trial Summary

The primary objectives of this study are:

1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate

2. To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC

The secondary objectives are:

1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive SCLC as measured by duration of response, progression-free survival and overall survival

2. To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard (IPM)

The exploratory objectives of this trial are:

1. To evaluate the effect of glufosfamide on lung cancer symptoms

2. To evaluate the role of tumor cell glucose transporter expression on the efficacy of glufosfamide

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00435578
Study type Interventional
Source Threshold Pharmaceuticals
Contact
Status Terminated
Phase Phase 2
Start date February 2007
Completion date November 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT00037713 - Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Phase 3
Recruiting NCT02736916 - HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer N/A
Terminated NCT00637624 - N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy N/A
Completed NCT00308529 - Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Active, not recruiting NCT01306045 - Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase 2
Completed NCT00294931 - Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Terminated NCT00265200 - Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer Phase 2
Completed NCT00270166 - The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy Phase 3
Completed NCT02936323 - PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Phase 1/Phase 2
Terminated NCT03699956 - RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer Phase 3
Completed NCT00263731 - Metabolomic Analysis of Lung Cancer
Active, not recruiting NCT04622228 - Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04253145 - Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. Phase 1/Phase 2
Terminated NCT04308785 - A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05566041 - A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer Phase 3
Completed NCT03083691 - BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Phase 2
Not yet recruiting NCT03871205 - Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer Phase 1